Few industries provide the same kind of dividend power as big pharma. Between top-selling drugs, cash-cow medications, and up-and-coming blockbusters, pharmaceutical companies like Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) boast the financial fortitude and portfolio firepower to provide for dividend investors for years to come.
Yet in an industry as competitive as this, which are the best stocks for dividend investors to target? Johnson & Johnson's breadth has provided a strong, stable base for dividend investors for the long term, but with the company's medical device business slowing, is this stock slumping out of the top segment of health care stocks?
Not to worry, Johnson & Johnson investors. In the video below, Fool contributor Dan Carroll shows you three big pharma stocks -- including J&J -- that have the potential to transform portfolios in the long run and deliver the types of dividends that will reward investors handsomely for years to come.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
